My Pretty Poppy

https://digitalcommons.library.umaine.edu/mmb-vp/3315/thumbnail.jp

My Little Rose Of Romany

https://digitalcommons.library.umaine.edu/mmb-vp/2205/thumbnail.jp

Salvation Rose

[Verse 1] I keep a flower deep in my heart, One little red little rose Mem’ries have made it so dear to me, And that’s why it grows and grows Salvation Rose, bloom for aye You’re in my heart there to stay. [Chorus] My Salvation Rose, My Salvation Rose, When our hearts were sad and sorrow was near, It was you who brought us comfort and cheer, You were a friend in need, You’re a friend indeed You will never, never die, I know, For it’s in God’s own garden that you grow, There’s the soul of an angel in you My Salvation Rose [Verse 2] Roses may wither and pass away, Sunbeams may be hard to see Still little rose, I will bring to you, The sunshine you once brought me I’ve set your heart for my goal I’ve planted you in my soul. [Chorus

Alternatives to NMD

Chapter VI of the LAWS "White Paper on National Missile Defense" - "In the fall of 2000, the United States will decide whether or not to begin deployment of a national missile defense (NMD) system. This White Paper reviews the technological aspects of the U.S. NMD program as well as its political and strategic impact and concludes that the current system, if deployed, would result in a net decrease in U.S. security."In Chapter VI, Steve Fetter and Jack Mendelsohn outline Alternatives to NMD. There exists an effective alternative to NMD for dealing with the potential ballistic missile threat: strengthening the interlocking and complementary barriers to proliferation created by deterrence, arms control (including transparency measures), economic incentives, cooperative programs, export controls, preemption and civil defense

Effectiveness, safety and cost-effectiveness of vaporized nicotine products versus nicotine replacement therapy for tobacco smoking cessation in a low-socioeconomic status Australian population: a study protocol for a randomized controlled trial

Background: In Australia, tobacco smoking rates have declined but inequalities remain with significantly higher smoking prevalence among low-socioeconomic populations. Clinical trial data suggest vaporized nicotine products (VNPs) aid smoking cessation. Most VNP trials have used refillable tank systems, but newer generation (pod) devices now comprise the largest market share yet have limited clinical trial evidence on safety and effectiveness. This study evaluates the effectiveness, safety and cost-effectiveness of VNPs (pod and tank device) compared with nicotine replacement therapy ([NRT]—gum or lozenge) for smoking cessation. Methods: This is a two-arm, open-label, superiority, parallel group, randomized controlled trial (RCT) with allocation concealment and blinded outcome assessment. The RCT is conducted at the National Drug and Alcohol Research Centre at the University of New South Wales, Sydney, Australia. Participants are people who smoke daily, are interested in quitting and receive a government pension or allowance (N = 1058). Participants will be randomized (1:1 ratio) to receive 8 weeks of free: VNPs, with pod (40 mg/mL nicotine salt) and tank device (18 mg/mL freebase nicotine) in mixed flavours; or NRT (gum or lozenge; 4 mg). All participants will receive daily text message behavioural support for 5 weeks. Assessments will be undertaken by telephone at baseline, with three follow-up calls (two check-in calls within the first month and final follow-up at 7 months post randomization) to ascertain smoking status, treatment adherence and adverse events. The primary outcome is 6-month continuous abstinence verified by carbon monoxide breath test of ≤5ppm at 7-month follow-up. Safety and cost-effectiveness of VNPs versus NRT will also be evaluated. Discussion: Further data are required to strengthen certainty of evidence for VNPs aiding smoking cessation, particularly for newer generation pod devices. To our knowledge, this trial is the first to offer choice of VNPs and no comparative effectiveness trial data exists for new pod devices. If effective, the findings can inform wider implementation of VNPs to aid smoking cessation in a priority group. Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12621000076875. Registered on 29 January 2021. https://www.anzctr.org.a

Is sleep disruption a risk factor for Alzheimer’s disease?

Sleep disturbances are routinely encountered in Alzheimer’s disease (AD) and affect about 25–40% of patients in the mild-to-moderate stages of the disease. In many, sleep pathology may represent a symptom of the underlying neurodegeneration. However, a history of sleep disruption occurring years prior to onset of cognitive symptoms could represent a potential risk factor for AD. The aim of the present narrative review was to evaluate current evidence linking sleep disturbances with AD development and to understand the mechanisms that may contribute to this. Although the mechanisms by which poor sleep may contribute to AD genesis is not fully understood, emerging evidence linking disturbances in the sleep wake cycle with Aβ deposition is shedding light on the relationship between sleep pathology and the subsequent development of AD. Aβ burden appears to be enhanced by sleep-wake cycle disruptions and is suspected as being an important mechanism by which sleep disruptions contribute in AD development. Other mechanisms triggered by sleep disruption may also be involved in AD development, such as brain hypoxia, oxidative stress, circadian activity rhythms disturbances, overexpression of orexins, and blood-brain barrier impairment. Further understanding of the link between sleep disturbances and future development of AD is still needed before sleep disturbances are clearly marked as a preventable risk factor for AD. In these circumstances, early lifestyle interventions to help increase the quantity and quality of sleep may have a favorable outcome on decreasing the incidence of AD and this needs to be investigated further

Inhibition of retrieval in hypnotic amnesia:Dissociation by upper-alpha gating

Hypnotic amnesia is a functional dissociation from awareness during which information from specific neural processes is unavailable to consciousness. We test the proposal that changes in topographic patterns of cortical oscillations in upper-alpha (10–12 Hz) band selectively inhibit the recall of memories during hypnotic amnesia by blocking availability of locally processed information at specific points in retrieval. Participants were prescreened for high or low hypnotic susceptibility. Following hypnotic induction, participants were presented with a series of 60 face stimuli and were required to identify affective expressions. Participants received a suggestion for amnesia for these faces. They were then presented with a set of 30 old and 30 new faces and identified each as old or new. Amnesia suggestion was lifted and recall tested using the remaining 30 old faces and another 30 new faces. Exact Low Resolution Brain Electromagnetic Tomography source analyses are reported for 64 channel event-related electroencephalogram recorded from highs showing reversible amnesia to old faces. For high-susceptible participants, the amnesia suggestion significantly increased old faces wrongly identified while for low-susceptible participants amnesia suggestion increased the new faces wrongly identified. There were no differences between high- and low-susceptible participants following reversal of the suggestion. For previously seen faces which were wrongly identified, compared to new faces correctly identified, (late) evoked upper-alpha is significantly higher in right BA7 in a region implicated in top-down executive control to assist recall of visual information. Lagged nonlinear connectivity between cortical sources in upper-alpha in the same condition showed significantly increased connectivity between right BA34 (parahippocampal gyrus) and right BAs 7, 20 and 22. Integration between these regions is essential for recall of recent faces. During amnesia, spatial and temporal coordination of upper-alpha appears to suppress integrated functioning of these regions (hence recall). These patterns were absent after reversal of amnesia suggestion

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel strategy for identifying customized combinations of triplets of targeted agents, utilizing a simplified interventional mapping system (SIMS) that merges knowledge about existent drugs and their impact on the hallmarks of cancer. Based on interrogation of matched lung tumor and normal tissue using targeted genomic sequencing, copy number variation, transcriptomics, and miRNA expression, the activation status of 24 interventional nodes was elucidated. An algorithm was developed to create a scoring system that enables ranking of the activated interventional nodes for each patient. Based on the trends of co-activation at interventional points, combinations of drug triplets were defined in order to overcome resistance. This methodology will inform a prospective trial to be conducted by the WIN consortium, aiming to significantly impact survival in metastatic NSCLC and other malignancies